Where it trades today
trading 65% of the way up its 52-week range
How the price has moved
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- AMGN is valued near its sector range at 24.0x earnings versus 22.0x for peers, so the next move likely needs a real earnings or guidance catalyst.
- Recent realized volatility is running around 40.6%, above the sector norm of 22.0%, so position sizing matters more than usual.
- AMGN remains in a bearish short-term trend and sits 13.7% below its high, which raises the bar for any thesis that depends on fast multiple expansion.
Portfolio Use Case
- AMGN is more relevant for investors who want some income support alongside price appreciation, not just pure growth exposure.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in AMGN.
- A recovery in price alone would not be enough to improve the view; the thesis needs confirmation from improving business or valuation signals.
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
Methodology
- Price, market cap, beta, yield, and liquidity fields for AMGN come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for AMGN. Last refresh: Sep 18, 2026, 10:56 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Amgen Inc. does
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple…
Employees
31,500
Industry
Drug Manufacturers - General
Headquarters
Thousand Oaks, United States
What analysts expect
AMGN carries a hold consensus from 29 analysts, with an average price target of $387.69 versus $385.65 today (+0.5%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
AMGN generated $38.09B in trailing revenue (9.5% year over year), with a 23.0% net margin, and $8.65B of free cash flow, against $43.31B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $36.75B | $24.71B | $9.08B | $7.71B | $14.33 | $8.10B |
| 2024 | $33.42B | $20.57B | $7.26B | $4.09B | $7.62 | $10.39B |
| 2023 | $28.19B | $19.74B | $7.90B | $6.72B | $12.56 | $7.36B |
| 2022 | $26.32B | $19.92B | $9.57B | $6.55B | $12.18 | $8.79B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
AMGN beside the healthcare names it is usually measured against.
What the chart is saying
Amgen Inc. trades at $385.65, 13.7% below its 52-week high. With a beta of 0.43, it shows less sensitivity to what the wider market does.
Questions people ask about it
Is AMGN a good buy right now?
Amgen Inc. trades at 24.0x earnings. This is near market average. Current risk level is High based on 40.6% volatility.
Does AMGN pay dividends?
Yes, Amgen Inc. offers a dividend yield of 2.65%. That is roughly $10.22 per share a year.
How volatile is AMGN?
With 30-day annualized volatility of 40.6% and beta of 0.43, AMGN is classified as High risk. The stock tends to be more stable than the market average.
What is the analyst price target for AMGN?
The average analyst price target for Amgen Inc. (AMGN) is $387.69 based on 29 analyst estimates, about 0.5% above the current price of $385.65. The published range runs from $225.00 to $457.00.
How much revenue does AMGN generate?
Amgen Inc. reported $38.09B in trailing twelve-month revenue. Revenue growth is running at 9.5% year over year. Net margin sits at 23.0%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.